Charles River Laboratories | CRL - Operating Profit

Stock Price
201.62
Daily Change
0.21 0.10%
Monthly
-3.22%
Yearly
21.55%
Q1 Forecast
204.00

Charles River Laboratories reported $133.8M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Agilent USD 443M 66M Sep/2025
Align Technology USD 184.65M 21.61M Sep/2025
Bio-Rad Laboratories USD 77.1M 53.4M Jun/2025
Bruker USD 83.9M 72M Sep/2025
Cardinal Health USD 754M 125M Sep/2025
Charles River Laboratories USD 133.8M 1.46M Sep/2025
Cigna USD 2.75B 240M Sep/2025
CVS Health USD 2.95B 339M Sep/2025
Danaher USD 1.5B 348M Dec/2025
Dentsply International USD 512M 401M Sep/2025
Elevance Health USD 581M 1.18B Dec/2025
Galapagos EUR -41.67M 15.36M Sep/2025
Hologic USD 237M 16M Dec/2025
Humana USD 400M 698M Sep/2025
Illumina USD 250M 5M Sep/2025
Incyte USD 431.31M 120.49M Sep/2025
IQVIA Holdings USD 573M 17M Sep/2025
Laboratory Of America USD 397.3M 65.5M Sep/2025
Lonza CHF 430M 104M Dec/2024
McKesson USD 1.5B 413M Sep/2025
Merck EUR 1.21B 180M Sep/2025
Mettler Toledo International USD 294.2M 28.49M Sep/2025
Novartis USD 4.5B 363M Sep/2025
Pfizer USD 4.65B 3.99B Dec/2025
Quest Diagnostics USD 386M 52M Sep/2025
Revvity USD 98.34M 8.63M Sep/2025
Thermo Fisher Scientific USD 2.3B 226M Dec/2025
United Therapeutics USD 389.3M 112.4M Sep/2025
UnitedHealth USD 3.26B 1.06B Dec/2025
Waters USD 192.11M 3.9M Sep/2025
West Pharmaceutical Services USD 167.6M 13.9M Sep/2025